Evidence map›Paper›PMID 36505476›Full record

ReviewFrontiers in immunology2022

Viruses utilize ubiquitination systems to escape TLR/RLR-mediated innate immunity.

Shanzhi Huang, Anchun Cheng, Mingshu Wang, Zhongqiong Yin, Juan Huang, Renyong Jia

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.0field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. The strategies and advances of mRNA translation booster.Asian journal of pharmaceutical sciences · 2025
    Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Shanzhi HuangAvian Disease Research Center, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, China.
Anchun ChengAvian Disease Research Center, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, China.
Mingshu WangAvian Disease Research Center, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, China.
Zhongqiong YinKey Laboratory of Animal Disease and Human Health of Sichuan Province, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, China.
Juan HuangAvian Disease Research Center, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, China.
Renyong JiaAvian Disease Research Center, College of Veterinary Medicine, Sichuan Agricultural University, Chengdu, China.
Sichuan Agricultural University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

When the viruses invade the body, they will be recognized by the host pattern recognition receptors (PRRs) such as Toll like receptor (TLR) or retinoic acid-induced gene-I like receptor (RLR), thus causing the activation of downstream antiviral signals to resist the virus invasion. The cross action between ubiquitination and proteins in these signal cascades enhances the antiviral signal. On the contrary, more and more viruses have also been found to use the ubiquitination system to inhibit TLR/RLR mediated innate immunity. Therefore, this review summarizes how the ubiquitination system plays a regulatory role in TLR/RLR mediated innate immunity, and how viruses use the ubiquitination system to complete immune escape.

Indexed as

Toll-Like ReceptorsVirusesAntiviral AgentsImmunity, InnateUbiquitinationAntiviral AgentsToll-Like ReceptorsE3 ubiquitin ligaseinnate immuneRLRTLRubiquitinationvirus

Identifiers

PMID36505476
PMCPMC9732732
OpenAlexW4310044579

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.